These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Canaccord Genuity has downgraded Pliant (PLRX) to hold following news that the company has paused a clinical trial for its ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
Pliant Therapeutics shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors. Shares traded 55% lower ahead ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback